Derek Archila

Q: What is Derek Archila's success rate?

Derek Archila currently has a success rate of 70.96970405016617.

Q: What is the average return of Derek Archila's calls?

Their stock ratings have generated an average return of 31.381998326559483.

Wells Fargo | Healthcare

Derek Archila is an analyst from Wells Fargo specializing in the Healthcare sector. Ranked #1771 out of 4706 analysts, they have issued 82 stock ratings with a success rate of 70.97% and an average return of 31.38%.

Derek Archila has a well-established track record, with 82 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 70.97% and an average return of 31.38%, underscoring their expertise and ability to identify winning opportunities for investors.

#1771

Out of 4706

Total Ratings

+70.97%

Success Rate

+31.38%

Average Return

Recent Ratings Analysis

VRDN

Buy

Jun 29, 2026

Target

$31.00

Current

$18.79

Performance

0.00%

Derek Archila rated VRDN as Overweight on Jun 29, 2026, setting a price target of 31. Shares have remained stable near 18.79, leaving the 31 target still in play.

RYTM

Buy

Jun 15, 2026

Target

$155.00

Current

$110.04

Performance

22.68%

On Jun 15, 2026, RYTM was given a Overweight rating by Derek Archila, with a target price of 155. The stock rallied 22.68% after the rating, narrowing the gap to the target of 155 and validating the bullish stance.

NRIX

Buy

Jun 08, 2026

Target

$25.00

Current

$23.85

Performance

52.49%

NRIX received a Overweight rating from Derek Archila on Jun 08, 2026, aiming for 25. Momentum has favored the Buy call, with shares climbing from 23.85 to 23.85, rewarding those who trusted the recommendation.

TRAX

Buy

Jun 08, 2026

Target

$30.00

Current

$17.01

Performance

8.00%

On Jun 08, 2026, Derek Archila published a Overweight outlook on TRAX, with a target of 30. Shares gained 8.00%, underscoring the accuracy of the bullish outlook toward 30.

ARGX

Buy

Jun 01, 2026

Target

$1291.00

Current

$912.46

Performance

9.13%

Derek Archila on Jun 01, 2026 assigned ARGX a Overweight rating, with a price target of 1291. The Buy call aligned well with market performance, producing a gain of 9.13%.

ALMS

Buy

May 15, 2026

Target

$51.00

Current

$27.14

Performance

18.67%

On May 15, 2026, Derek Archila reaffirmed ALMS with a Overweight rating, targeting 51. The recommendation was supported by strong follow-through as the stock rose from 27.14 to 27.14.

CABA

Hold

May 15, 2026

Target

$4.00

Current

$3.11

Performance

-6.04%

CABA was rated Equal-Weight by Derek Archila on May 15, 2026, with a price objective of 4. Investors who stayed cautious avoided some of the 6.04% decline.

CLDX

Buy

May 13, 2026

Target

$54.00

Current

$37.44

Performance

15.16%

On May 13, 2026, Derek Archila initiated coverage on CLDX with a Overweight rating and target of 54. The stock’s climb of 15.16% since the call highlights the foresight in the rating.

ASND

Buy

May 08, 2026

Target

$326.00

Current

$263.70

Performance

10.49%

Derek Archila issued a Overweight recommendation for ASND on May 08, 2026, price target set at 326. Investors following the Buy call captured upside momentum, with shares now at 263.7.

ALNY

Hold

May 01, 2026

Target

$377.00

Current

$293.52

Performance

—

On May 01, 2026, ALNY was evaluated by Derek Archila, who gave a Equal-Weight rating and target of 377. Hold sentiment was validated by subdued trading with no breakout beyond 293.52.

SLNO

Hold

Apr 17, 2026

Target

$53.00

Current

$53.01

Performance

0.44%

Derek Archila rated SLNO as Equal-Weight on Apr 17, 2026, setting a price target of 53. The Hold stance appears justified, as shares hovered around 53.01 with a 0.44% move.

APLS

Hold

Apr 17, 2026

Target

$41.00

Current

$41.03

Performance

0.32%

On Apr 17, 2026, APLS was given a Equal-Weight rating by Derek Archila, with a target price of 41. Market indecision, reflected in sideways trading near 41.03, supported the cautious call.

ALXO

Buy

Mar 19, 2026

Target

$5.00

Current

$2.20

Performance

0.46%

ALXO received a Overweight rating from Derek Archila on Mar 19, 2026, aiming for 5. Price action was muted, as shares hovered around 2.2 despite the bullish outlook.

GLUE

Buy

Mar 18, 2026

Target

$29.00

Current

$23.90

Performance

51.65%

On Mar 18, 2026, Derek Archila published a Overweight outlook on GLUE, with a target of 29. Shares gained 51.65%, underscoring the accuracy of the bullish outlook toward 29.

SEPN

Buy

Mar 03, 2026

Target

$48.00

Current

$34.75

Performance

23.53%

Derek Archila on Mar 03, 2026 assigned SEPN a Overweight rating, with a price target of 48. The Buy call aligned well with market performance, producing a gain of 23.53%.

IRON

Buy

Mar 02, 2026

Target

$79.00

Current

$74.50

Performance

11.96%

On Mar 02, 2026, Derek Archila reaffirmed IRON with a Overweight rating, targeting 79. The recommendation was supported by strong follow-through as the stock rose from 74.5 to 74.5.

BBIO

Buy

Feb 13, 2026

Target

$98.00

Current

$72.01

Performance

-4.31%

BBIO was rated Overweight by Derek Archila on Feb 13, 2026, with a price objective of 98. The stock is in a wait-and-see zone, leaving the Buy case open-ended.

INCY

Hold

Feb 11, 2026

Target

$107.00

Current

$114.66

Performance

16.01%

On Feb 11, 2026, Derek Archila initiated coverage on INCY with a Equal-Weight rating and target of 107. The Hold stance underestimated the stock’s strength as it gained 16.01%.

VTYX

Hold

Jan 08, 2026

Target

$14.00

Current

$14.00

Performance

1.16%

Derek Archila issued a Equal-Weight recommendation for VTYX on Jan 08, 2026, price target set at 14. The rating was appropriate for a consolidating market trading near 14.

KYTX

Buy

Dec 16, 2025

Target

$33.00

Current

$8.78

Performance

-14.26%

On Dec 16, 2025, KYTX was evaluated by Derek Archila, who gave a Overweight rating and target of 33. Investors saw limited payoff as shares fell short of the 33 target.

KYMR

Buy

Dec 09, 2025

Target

$116.00

Current

$109.32

Performance

25.83%

Derek Archila rated KYMR as Overweight on Dec 09, 2025, setting a price target of 116. The call has proven timely, with shares rising 25.83% toward the price target of 116.

ORIC

Buy

Dec 08, 2025

Target

$25.00

Current

$10.15

Performance

-3.47%

On Dec 08, 2025, ORIC was given a Overweight rating by Derek Archila, with a target price of 25. The stock traded sideways with a -3.47% move, keeping the bullish thesis unresolved.

ANNX

Buy

Nov 19, 2025

Target

$27.00

Current

$5.57

Performance

37.19%

ANNX received a Overweight rating from Derek Archila on Nov 19, 2025, aiming for 27. Momentum has favored the Buy call, with shares climbing from 5.57 to 5.57, rewarding those who trusted the recommendation.

ARVN

Buy

Nov 06, 2025

Target

$15.00

Current

$8.29

Performance

-17.10%

On Nov 06, 2025, Derek Archila published a Overweight outlook on ARVN, with a target of 15. Market action contradicted the Buy thesis, as shares slipped to 8.29.

ANAB

Buy

Nov 05, 2025

Target

$81.00

Current

$65.97

Performance

83.25%

Derek Archila on Nov 05, 2025 assigned ANAB a Overweight rating, with a price target of 81. The Buy call aligned well with market performance, producing a gain of 83.25%.

EXEL

Hold

Oct 21, 2025

Target

$30.00

Current

$54.28

Performance

50.24%

On Oct 21, 2025, Derek Archila reaffirmed EXEL with a Equal-Weight rating, targeting 30. Market strength beyond 54.28 went further than the conservative outlook suggested.

KZR

Hold

Oct 17, 2025

Target

$5.00

Current

$7.29

Performance

14.62%

KZR was rated Equal-Weight by Derek Archila on Oct 17, 2025, with a price objective of 5. Despite caution, upside momentum rewarded risk-takers with gains to 7.29.

CCCC

Buy

Sep 23, 2025

Target

$10.00

Current

$4.35

Performance

67.95%

On Sep 23, 2025, Derek Archila initiated coverage on CCCC with a Overweight rating and target of 10. The stock’s climb of 67.95% since the call highlights the foresight in the rating.

ATYR

Hold

Sep 16, 2025

Target

$1.00

Current

$0.57

Performance

-47.56%

Derek Archila issued a Equal-Weight recommendation for ATYR on Sep 16, 2025, price target set at 1. Market action validated the conservative Hold outlook with shares at 0.5664.

STRO

Hold

Aug 12, 2025

Target

$3.00

Current

$33.35

Performance

325.55%

On Aug 12, 2025, STRO was evaluated by Derek Archila, who gave a Equal-Weight rating and target of 3. Investors who stayed in despite the Hold saw upside of 325.55%.

ZNTL

Hold

Aug 07, 2025

Target

$5.00

Current

$4.61

Performance

217.93%

Derek Archila rated ZNTL as Equal-Weight on Aug 07, 2025, setting a price target of 5. Despite the Hold call, shares climbed 217.93% to 4.61, revealing unexpected momentum.

BPMC

Hold

Jun 17, 2025

Target

$129.00

Current

$129.46

Performance

0.96%

On Jun 17, 2025, BPMC was given a Equal-Weight rating by Derek Archila, with a target price of 129. Market indecision, reflected in sideways trading near 129.46, supported the cautious call.

QTTB

Hold

Mar 12, 2025

Target

$15.00

Current

$14.14

Performance

644.21%

QTTB received a Equal-Weight rating from Derek Archila on Mar 12, 2025, aiming for 15. Investors saw gains of 644.21% that the cautious stance didn’t fully capture.

ZYME

Hold

Dec 19, 2024

Target

$14.00

Current

$24.10

Performance

77.47%

On Dec 19, 2024, Derek Archila published a Equal-Weight outlook on ZYME, with a target of 14. The Hold call missed some of the bullish momentum as shares advanced toward 14.

IMVT

Buy

Dec 19, 2024

Target

$45.00

Current

$38.51

Performance

50.08%

Derek Archila on Dec 19, 2024 assigned IMVT a Overweight rating, with a price target of 45. The Buy call aligned well with market performance, producing a gain of 50.08%.

SLRN

Buy

Dec 11, 2024

Target

$13.00

Current

$2.27

Performance

-33.43%

On Dec 11, 2024, Derek Archila reaffirmed SLRN with a Overweight rating, targeting 13. Shares slid 33.43% despite the recommendation, highlighting downside risks.

MOR

Hold

Mar 14, 2024

Target

$18.25

Current

$18.96

Performance

5.69%

MOR was rated Equal-Weight by Derek Archila on Mar 14, 2024, with a price objective of 18.25. Despite caution, upside momentum rewarded risk-takers with gains to 18.96.

Frequency Asked Questions

Who is Derek Archila?

Derek Archila is an analyst from Wells Fargo specializing in the Healthcare sector.

What is Derek Archila's success rate?

Derek Archila currently has a success rate of +70.97%.

How many ratings has Derek Archila issued?

Derek Archila has issued 82 stock ratings so far.

What is the average return of Derek Archila's calls?

Their stock ratings have generated an average return of +31.38%.

What is Derek Archila's ranking?

Derek Archila is ranked #1771 out of 4706 analysts.

What types of ratings does Derek Archila give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Derek Archila?

You can follow Derek Archila by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Derek Archila?

Their latest rating was a Buy on VRDN issued on 2026-06-29.